Clik here to view.
A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D
Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to...
View ArticleClik here to view.
Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz...
Cross-border biotech Anji Pharma closed $70 million in Series B funding to advance a drug pipeline that includes metabolic and cancer drugs. The biotech’s business model of finding promising drugs and...
View ArticleClik here to view.
Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with...
Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending...
View ArticleClik here to view.
ShouTi secures $100M to hit biologic and peptide targets with small molecules
ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to...
View ArticleClik here to view.
Synbio startup GRObio gets $25M to work with new building blocks for protein...
Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup’s research...
View ArticleClik here to view.
Fat-shedding pill’s data lead to a $132M funding round for startup Rivus Pharma
Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new...
View ArticleClik here to view.
Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug
Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule...
View ArticleClik here to view.
Madrigal Drug Meets FDA’s Twin Goals for NASH, Paving Way for FDA Filing
A Madrigal Pharmaceuticals drug for the fatty liver disease NASH has data from a pivotal clinical trial showing improvements in the organ. Based on those results, which sent Madrigal’s stock price...
View ArticleClik here to view.
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug
Sanofi is acquiring rights to a Maze Therapeutics drug candidate for Pompe disease that could give the pharmaceutical giant another option to offer patients who have the rare metabolic disorder. In...
View ArticleClik here to view.
Ionis Posts Trial Data in Rare Disease That Position It to Finally Set Out on...
Ionis Pharmaceuticals’ olezarsen has Phase 3 results showing the therapy handily beat a placebo at reducing fat levels in the blood due to a rare, inherited metabolic disorder with no FDA-approved...
View ArticleClik here to view.
Novo Nordisk’s Star Diabetes & Obesity Drug Shows Promise in Kidney Disease
A study testing Novo Nordisk’s semaglutide in chronic kidney disease is ending early after an interim analysis met efficacy goals. Detailed results are not yet available, but they could support...
View ArticleClik here to view.
Novo Nordisk Strikes Deal for Late-Stage Hypertension & Kidney Disease Drug
The KBP Biosciences drug Novo Nordisk is acquiring has reached Phase 3 testing as a potential treatment for uncontrolled hypertension and advanced chronic kidney disease. It’s the latest in a string of...
View ArticleClik here to view.
Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes...
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not...
View ArticleClik here to view.
Novo Nordisk Plans €2B Site Expansion as GLP-1 Drug Demand Grows
Novo Nordisk’s planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already...
View ArticleClik here to view.
Roche Lines Up $2.7B Acquisition to Join Chase for New Diabetes, Obesity Drugs
Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the...
View ArticleClik here to view.
Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a...
View ArticleClik here to view.
Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions,...
View ArticleClik here to view.
Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still...
Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically...
View ArticleClik here to view.
Boehringer Ingelheim’s Liver Drug Data Position It for MASH Clash With Eli Lilly
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends...
View ArticleClik here to view.
Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations
The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3...
View Article